The clinical and MRI associations were limited to the MS subsets and to the autoantibodies for which we had standardized titers (CSF114(Glc) IgG, CSF114(Glc) IgM, KIR4.1a IgG, KIR4.1a IgM, KIR4.1b IgG, KIR4.1b IgM, Ox-LDL and RF Screen) and to anti-DNA positivity status, the only antigen that had sufficient number (n ≥ 30) or more positive MS subjects. This evidence concerns the gene CD40LG and myeloid sarcoma.